texas oncology more breakthroughs. more victories
Some of our cancer centers may have important notifications found on the location page. View More Important Notifications x

Andrew J. Brenner, M.D., Ph.D.

Andrew J. Brenner, M.D., Ph.D. Photo

Provider Type: Physician

Specialties:
Board Certifications:
  • Internal Medicine
  • Medical Oncology
  • Neuro Oncology

Downloads

Education

  • Fellowship in Medical Oncology
    The University of Texas Health Science Center at San Antonio, San Antonio, TX
  • Residency in Internal Medicine
    Texas A&M Health Science Center College of Medicine at Scott & White Hospital and Clinic, Temple, TX
  • Medical Doctorate
    Texas Tech University Health Sciences Center School of Medicine, Lubbock, TX
  • Post Doctoral Fellowship in Tumor Biology
    European Institute of Oncology, Milan, Italy
  • Doctorate of Philosophy, Tumor Biology
    The University of Texas MD Anderson Cancer Center, Austin, TX
  • Post Doctoral Fellowship in Tumor Biology/Breast Cancer
    The Virginia Harris Cockrell Cancer Research Center at The University of Texas MD Anderson Cancer Center, Smithville, TX

Accolades & Memberships

  • American Association for Cancer Research
  • American Society of Clinical Oncology
  • European Society of Medical Oncology
  • Society for Neuro-Oncology
  • Texas Medical Association
  • Texas Society of Medical Oncology

Publications

  • Primary Diffuse Large B-Cell Lymphoma in a Patient with Rubinstein-Taybi Syndrome: Case Report and Review of the Literature

    World Neurosurgery, 2018

  • Hypoxia Activated Evofosfamide for Treatment of Recurrent Bevacizumab-Refractory Glioblastoma: A phase I Surgical Study

    Neuro-Oncology, 2018

  • Differential Effects of Estrogen Receptor β Isoforms on Glioblastoma Progression

    Cancer Research, 2018

  • First Results on Survival from a Large Phase 3 Clinical Trial of an Autologous Dendritic Cell Vaccine in Newly Diagnosed Glioblastoma

    Journal of Translational Medicine, 2018

  • Multiplatform Profiling of Meningioma Provides Molecular Insight and Prioritization of Drug Targets for Rational Clinical Trial Design

    Journal of Neuro-Oncology, 2018

Show all Publications
  • Metabolomic Signature of Brain Cancer

    Molecular Carcinogenesis, 2017

  • Phase I Study of MRX34, a Liposomal miR-34a Mimic, Administered Twice Weekly in Patients with Advanced Solid Tumor

    Investigational New Drugs, 2017

  • Novel KDM1A Inhibitors Induce Differentiation and Apoptosis of Glioma Stem Cells via Unfolded Protein Response Pathway

    Oncogene, 2017

  • Hypoxia in Astrocytic Tumors and Implications for Therapy

    Neurobiology of Disease, 2016

  • Selective Estrogen Receptor β Agonist LY500307 as a Novel Therapeutic Agent for Glioblastoma

    Scientific Reports, 2016

  • VB-111: A Novel Anti-Vascular Therapeutic for Glioblastoma Multiforme

    Journal of Neuro-oncology, 2015

  • Fungal Metabolite Ophiobolin A as a Promising Anti-Glioma Agent: In Vivo Evaluation, Structure-Activity Relationship and Unique Pyrrolylation of Primary Amines

    Bioorganic & Medicinal Chemistry Letters, 2015

  • Obesity Suppresses Estrogen Receptor Beta Expression in Breast Cancer Cells via a HER2-Mediated Pathway

    PloS One, 2015

  • Activity of 2-Aryl-2-(3-Indolyl) Acetohydroxamates Against Drug-Resistant Cancer Cells

    Journal of Medicinal Chemistry, 2015

  • Osteolytic Calvarial Lesions as Initial Presentation of Latent Neurosyphilis

    Journal of Clinical Neuroscience, 2015

  • Obesity-Associated Systemic Interleukin-6 Promotes Pre-Adipocyte Aromatase Expression via Increased Breast Cancer Cell Prostaglandin E2 Production

    Breast Cancer Research and Treatment, 2015

  • Predicting Success in Regulatory Approval from Phase I Results

    Cancer Chemotherapy and Pharmacology, 2014

  • NSAID Use Reduces Breast Cancer Recurrence in Overweight and Obese Women: Role of Prostaglandin-Aromatase Interactions

    Cancer Research, 2014

  • Image-Guided Interventional Therapy for Cancer with Radiotherapeutic Nanoparticles

    Advanced Drug Delivery Reviews, 2014

  • Clinical Outcomes and Survival of Advanced Renal Cancer Patients in Phase I Clinical Trials

    Clinical Genitourinary Cancer, 2014

  • Obesity Enhances Nongenomic Estrogen Receptor Crosstalk with the PI3K/Akt and MAPK Pathways to Promote in vitro Measures of Breast Cancer Progression

    Breast Cancer Research, 2013

  • Phase I Dose-Escalation Study of VB-111, an Antiangiogenic Virotherapy, in Patients with Advanced Solid Tumors

    Clinical Cancer Research, 2013

  • Phase I Study of GRN1005 in Recurrent Malignant Glioma

    Clinical Cancer Research, 2013

  • KDM1 Is a Novel Therapeutic Target for the Treatment of Gliomas

    Oncotarget, 2013

  • The Enhancing Effects of Obesity on Mammary Tumor Growth and Akt/mTOR Pathway Activation Persist After Weight Loss and Are Reversed By RAD001

    Molecular Carcinogenesis, 2013

  • The Oncogenic RNA-Binding Protein Musashi1 Is Regulated by HuR via mRNA Translation and Stability in Glioblastoma Cells

    Molecular Cancer Research, 2012

  • Safety, Pharmacokinetics, and Activity of GRN1005, a Novel Conjugate of Angiopep-2, a Peptide Facilitating Brain Penetration, and Paclitaxel, in Patients with Advanced Solid Tumors

    Molecular Cancer Therapeutics, 2012

  • Therapeutic Significance of Estrogen Receptor β Agonists in Gliomas

    Molecular Cancer Therapeutics, 2012

  • Rhenium-186 Liposomes as Convection-Enhanced Nanoparticle Brachytherapy for Treatment of Glioblastoma

    Neuro-Oncology, 2012

  • Powered Bone Marrow Biopsy Procedures Produce Larger Core Specimens, with Less Pain, in Less Time Than with Standard Manual Devices

    Hematology Reports, 2011

  • The Oncogenic RNA-Binding Protein Musashi1 Is Regulated by Tumor Suppressor miRNAs

    RNA Biology, 2011

  • A Prospective Randomised Study of a Rotary Powered Device (OnControl) for Bone Marrow Aspiration and Biopsy

    Journal of Clinical Pathology, 2011

  • Common Toxicities of Mammalian Target of Rapamycin Inhibitors

    Targeted Oncology, 2011

  • RANK Ligand: Effects of Inhibition

    Current Oncology Reports, 2010

  • Rotary Powered Device for Bone Marrow Aspiration and Biopsy Yields Excellent Specimens Quickly and Efficiently

    Journal of Clinical Pathology, 2010

  • Heterogeneity in the Effect of Albumin and Other Resuscitation Fluids on Intracellular Oxygen Free Radical Production

    The Journal of Trauma, 2004

  • WWOX, the FRA16D Gene, Behaves as a Suppressor of Tumor Growth

    Cancer Research, 2001

  • Increased p16 Expression with First Senescence Arrest in Human Mammary Epithelial Cells and Extended Growth Capacity with p16 Inactivation

    Oncogene, 1998

  • Analysis of Telomerase Activity Levels in Breast Cancer: Positive Detection at the in Situ Breast Carcinoma Stage

    Clinical Cancer Research, 1997

  • The Genetics of Sporadic Breast Cancer

    Progress in Clinical and Biological Research, 1997

  • Preferential Loss of Expression of p16(INK4a) Rather than p19(ARF) in Breast Cancer

    Clinical Cancer Research, 1996

  • Chromosome 9p Allelic Loss and p16/CDKN2 in Breast Cancer and Evidence of p16 Inactivation in Immortal Breast Epithelial Cells

    Cancer Research, 1995

  • A Quantitative Test for Copper Using Bicinchoninic Acid

    Analytical Biochemistry, 1995

Research Interest

Dr. Andrew Brenner is a nationally known expert in the treatment of brain and breast cancers, with a particular research interest in developing new treatments. He has served on multiple committees and panels including for the National Institutes of Health, National Cancer Institute, Department of Defense Breast Cancer Research Program, and others. He has also served on advisory committees for a number of companies to help direct development of new drugs. His laboratory work developing new treatments has been funded by the Food and Drug Administration, National Cancer Institute, and Cancer Prevention and Research Institute of Texas. He has published nearly 50 original research articles in peer reviewed journals.

Medical Practice

  • The University of Texas Health Science Center at San Antonio, Experimental Therapeutics Co-Leader, San Antonio, TX (April 2015 – Present)
  • The University of Texas Health Science Center at San Antonio, Cancer Therapy and Research Center Medical Director, San Antonio, TX (January 2015 – Present) 
  • Mays Cancer Center at UT Health San Antonio, Neuro-Oncology Physician, San Antonio, TX (July 2008 – Present) 
  • Baptist Health System, Oncology Unit Medical Director, San Antonio, TX (February 2013 – August 2015)
  • The University of Texas Health Science Center at San Antonio, Neuro-Oncology Program Co-Director, San Antonio, TX (July 2008 – Present)
  • The University of Texas Health Science Center at San Antonio, Hematology and Medical Oncology Fellowship Associate Program Director, San Antonio, TX (January 2009 – May 2014)

Related Stories

Other Information

Dr. Brenner is a college football fanatic and enjoys vinting wine and brewing beer in his free time. He also maintains an active lifestyle through weight lifting, mountain biking and spending time with his kids.